Single-dose, Parallel, Open-label Pharmacokinetic Study of FCN-437c Capsule in Subjects With Impaired Liver Function
Latest Information Update: 07 Oct 2024
At a glance
- Drugs FCN 437 (Primary)
- Indications HER2 negative breast cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Ahon Pharmaceutical
- 07 Oct 2024 New trial record